A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia Who Fail to Respond Adequately to Fimasartan Monotherapy
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Amlodipine/fimasartan/rosuvastatin (Primary) ; Amlodipine/fimasartan; Fimasartan; Rosuvastatin
- Indications Dyslipidaemias; Essential hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FIRST
- Sponsors Boryung Pharmaceutical
- 07 Jun 2019 Status changed from recruiting to completed.
- 09 Aug 2017 Status changed from not yet recruiting to recruiting.
- 19 May 2017 New trial record